Recombinant Human Granulocyte Colony-stimulating Factor（rhG-CSF）

A near miss incident involving a nurse mistakenly queuing filgrastim instead of pegfilgrastim highlights the challenges in community practice settings with biosimilar usage. Biosimilars, defined by the FDA as highly similar but not identical to reference biologics, have become essential in cancer care due to their lower costs and accelerated FDA approval. Nurses play a crucial role in their administration, verification, and patient education, ensuring the right medication is given to the right patient.

Experts discuss the use of sacituzumab govitecan and trastuzumab deruxtecan in breast cancer treatment, focusing on safety profiles, supportive care, and therapeutic sequencing. They highlight the importance of G-CSF use, the modest overall survival improvement with sacituzumab, and the better tolerability of trastuzumab deruxtecan. The discussion also covers the management of treatment-related toxicities, particularly neutropenia and diarrhea, and the need for early intervention with steroids to mitigate adverse effects.

Roche is a research-based healthcare company with two divisions: Pharmaceuticals and Diagnostics. Pharmaceuticals include Roche Pharmaceuticals and Chugai, while Diagnostics comprises Diabetes Care, Molecular Diagnostics, Professional Diagnostics, and Tissue Diagnostics. Roche develops medicines for oncology, immunology, infectious diseases, ophthalmology, and neuroscience, and offers products for researchers in cell analysis, gene expression, genome sequencing, and nucleic acid purification.

FDA approves Nypozi (filgrastim-txid), a biosimilar to Neupogen, indicated to decrease the incidence of infection in patients with non-myeloid malignancies.